Stock Alert: Acacia Communications Jumps 30% On New Merger Deal With Cisco

Shares of Acacia Communications Inc. (ACIA) surged 30% on Thursday morning after the company announced a new merger deal with Cisco Systems (CSCO) valued at $4.5 billion.

ACIA is currently trading at $113.65, up $27.20 or 31.46%, on the Nasdaq.

The optical component maker said it has agreed a new $4.5 billion merger deal with Cisco after an earlier deal was terminated by a delay in regulatory approval from China.

Cisco will pay $115 per share for Acacia, the company said. Regulators in the U.S., Germany and Austria had cleared the proposed takeover, but a delay in obtaining approval from China before a January 8 deadline caused Acacia to terminate the original deal.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT